Experimental Drug May Offer a ‘Functional Cure’ for Some People with Chronic Hepatitis B
An experimental drug called bepirovirsen shows promise as a potential cure for chronic hepatitis B. In clinical trials, about 20% of participants maintained undetectable virus levels for at least six months after treatment. The drug is currently being evaluated for approval by regulatory authorities.
- ▪Bepirovirsen is designed to limit the virus's ability to replicate and stimulate the immune system.
- ▪In Phase III trials, 19% of patients treated with bepirovirsen achieved a functional cure compared to 0% in the placebo group.
- ▪The drug's side effects were generally mild, though some patients experienced temporary increases in liver enzymes.
Opening excerpt (first ~120 words) tap to expand
An experimental medication called bepirovirsen might represent the first successful step toward a major medical milestone: a cure for chronic hepatitis B. A study out this week shows that it can effectively clear the viral disease from some people’s bodies.cnx.cmd.push(function(){cnx({"playerId":"92b7b46b-43ed-4e0e-b21b-2c999302d9d7","settings":{"advertising":{"macros":{"AD_UNIT":"/23178111854/od.gizmodo.com/article","CHILD_UNIT":"article","POST_ID":"2000765066","POST_TYPE":"post","CHANNEL":"science","SECTION":"health","SUBSECTION":"","CATEGORIES":"health","TAGS":"experimental-drugs,hepatitis-b,viral-infections","NOP":"0"},"timeBeforeFirstAd":0}}}).render("cnx-player-main")}); On Thursday, the makers of bepirovirsen, GSK (formerly GlaxoSmithKline), announced the results of its two Phase…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Gizmodo.
Discussion
0 commentsMore from Gizmodo
